3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
4
Neoplasm Metastasis
3
Neoplasms by Site
2
Neoplasms
2
Breast Diseases
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Skin Diseases
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
Gemcitabine
7
Cisplatin
6
durvalumab
5
pembrolizumab
4
gemcitabine-oxaliplatin regimen
3
S 1 (combination)
3
Carboplatin
3
Trastuzumab
2
Paclitaxel
2
Capecitabine
2
tucatinib
1
tremelimumab
1
merestinib
1
irinotecan sucrosofate
1
envafolimab
1
Tegafur
1
Ramucirumab
1
Radiation
1
Psilocybin
1
Poly(ADP-ribose) Polymerase Inhibitors
1
Pemetrexed
1
Oxaliplatin
1
Nivolumab
1
Leucovorin
1
Itraconazole
1
Immune Checkpoint Inhibitors
1
High-Throughput Nucleotide Sequencing
1
Fulvestrant
1
Fluorouracil
1
Drug Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Biliary Tract Neoplasms
×
AZD9833
×
Clear all
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled